Ripetuti eccessi di esposizione ai raggi solari durante l’infanzia triplicano il rischio di sviluppare il melanoma da adulti. Per questo motivo i bambini vanno difesi dal sole con adeguate protezioni, evitando sempre le ore centrali della giornata, soprattutto con l’arrivo della bella stagione. Ma alla prevenzione si aggiungono nuove strumenti di cura efficaci per combattere questo tumore, immunoterapia e farmaci mirati su bersagli cellulari. Se ne è parlato al convegno nazionale dell’Associazione italiana di oncologi a medica (Aiom) intitolato Nuove frontiere nel trattamento del melanoma, tenutosi a Napoli. Oggi, infatti, si stanno affacciando nuove armi realmente efficaci, come l’immunoterapia che agisce stimolando le difese immunitarie contro le cellule tumorali con importante beneficio per i malati. Inoltre sono in via di registrazione anche in Italia farmaci mirati su bersagli cellulari da impiegare nei pazienti con melanoma metastatico che presentano specifiche alterazioni molecolari. I tempi tra la registrazione europea e la successiva approvazione dei nuovi farmaci in Italia sono purtroppo ancora lunghi. Gli oncologi chiedono che vengano velocizzati i processi registrativi per i trattamenti oncologici realmente innovativi come nel caso del melanoma. «La battaglia contro questa forma di cancro è difficile» spiega il professor Carmine Pinto, segretario nazionale Aiom «ma si può vincere ponendo più attenzione a semplici regole di prevenzione. Troppe persone si e spongono al sole senza precauzioni, in particolare i bambini rappresentano l’anello debole della catena. Un richiamo da tenere in considerazione soprattutto in questi mesi, in cui molti approfittano del fine settimana per prendere un po’ di colore. Vanno inoltre totalmente bandite le lampade abbronzanti che, secondo l’Agenzia internazionale per la ricerca sul cancro (Iarc), aumentano il rischio di melanoma del 75%, al pari del fumo di sigaretta, se utilizzate prima dei 30 anni». (fonte farmacista33)
Posts contrassegnato dai tag ‘cancer’
Pubblicato da fidest su martedì, 3 aprile 2012
Pubblicato da fidest su lunedì, 26 marzo 2012
Ottawa, Canada (PRNewswire) Nordion Inc. (TSX: NDN) (NYSE: NDZ), a leading provider of products and services for the prevention, diagnosis and treatment of disease, today launched a new custom dose feature in Europe and Canada for TheraSphere®, Nordion’s Y-90 microsphere treatment for liver cancer. Nordion has also filed a request with the Food and Drug Administration for approval of the custom dose feature in the United States.In addition to standard dose vial configurations, Nordion now offers an expanded range of TheraSphere treatment options with custom doses available in wider variety of increments. The custom doses are designed to provide greater treatment flexibility for physicians, save administration time and reduce product waste, while limiting unnecessary radiation exposure to patients and healthcare professionals.Nordion has also enhanced its Treatment Window Illustrator tool to demonstrate how custom doses can be selected and compared to standard dose vial configurations.Nordion is attending the Society of Interventional Radiology (SIR) Annual Scientific Meeting 2012, March 24-29, in San Francisco. Nordion representatives will be at Booth #1234 to talk about TheraSphere to physicians attending the conference. Nordion will host two “Eat and Be Educated” learning sessions at its booth:
TheraSphere is a liver cancer therapy that consists of millions of small glass beads (20 to 30 micrometers in diameter) containing radioactive yttrium-90 (Y-90). The product is injected by physicians into the artery of the patient’s liver through a catheter, which allows the treatment to be delivered directly to the tumour via blood flow. In the US, TheraSphere is used to treat patients with unresectable hepatocellular carcinoma (HCC), the most common form of primary liver cancer, and can be used as a bridge to surgery or transplantation in these patients. It is also indicated for the treatment of HCC patients with portal vein thrombosis (PVT). TheraSphere is approved by the U.S Food and Drug Administration (FDA) under a Humanitarian Device Exemption (HDE). HDE approvals are based on demonstrated safety and probable clinical benefit. However, effectiveness of the indication for use has not been established.
Nordion Inc. (TSX: NDN) (NYSE: NDZ) is a global health science company that provides market-leading products used for the prevention, diagnosis and treatment of disease. We are a leading provider of medical isotopes, targeted therapies and sterilization technologies that benefit the lives of millions of people in more than 60 countries around the world. Our products are used daily by pharmaceutical and biotechnology companies, medical-device manufacturers, hospitals, clinics and research laboratories. Nordion has more than 500 highly skilled employees in three locations. Find out more at http://www.nordion.com and follow us at http://twitter.com/NordionInc.
Pubblicato da fidest su lunedì, 19 marzo 2012
Copenhagen, (PRNewswire). Clinicians come together in Copenhagen to discuss the best approaches for future brain, prostate and lung cancer radiotherapy treatment. Today clinicians from around the world will gather at the 4th Brainlab European Radiotherapy User Meeting to share their best practice and experiences in treating difficult-to-treat cancers using advanced radiotherapy The two-day meeting held at the Global Center of Stereotactic Radiotherapy at Rigs Hospitalet, Copenhagen University Hospital, Denmark, aims to discuss the best approaches for future radiation treatment to achieve the best outcomes for patients. Over 170 clinicians from nearly 90 different international cancer centres will hear 33 different advanced approaches for treating cancers across the body using modern radiation therapy techniques. Highlights of the meeting will be keynote presentations on new protocols for the treatment of lung, prostate and brain cancers with radiosurgery. These protocols will show that radiosurgery can offer faster treatment times, shorter periods of treatment and in turn allows greater numbers of patients to be treated using the same advanced radiotherapy systems. Prostate Cancer clinical specialist Professor Raymond Miralbell, Head of Radiation Oncology at University Hospital Geneva, Switzerland, will present his experiences treating prostate cancer using a novel radiosurgery approach. Brainlab’s bi-annual Radiotherapy meeting immediately follows the launch of the Global Center of Stereotactic Radiotherapy at Rigs Hospitalet, launched to local clinicians the previous day. The facility is one of the most well equipped cancer centers worldwide with advanced technology that allows clinicians to both treat and research some of the most modern techniques available to patients.
Brainlab develops, manufactures and markets software-driven medical technology that supports targeted, less-invasive treatment. Core products are image-guided systems and software that provide real-time information used for surgical navigation and radiosurgical planning and delivery.Brainlab technology drives collaboration between hospitals and clinicians from a wide variety of subspecialties-from neurosurgery and oncology to orthopedics, ENT, CMF and spine and trauma. This integration delivers better access to improved and more efficient treatment.Founded in 1989, the privately held Brainlab group has more than 5,000 systems installed in over 80 countries. Based in Munich, Germany, Brainlab employs 1020 people in 17 offices worldwide.
Pubblicato da fidest su martedì, 28 febbraio 2012
London (PRNewswire) A new report by visiongain predicts that the world market for cancer-treating drugs will reach $75 billion for 2012. That revenue forecast appears in Leading Anti-Cancer Drugs and Associated Market 2012-2022, published in February 2012. Visiongain is a business information provider based in London, UK.The new study predicts that overall revenues for anti-cancer treatments will increase strongly from 2012 to 2022. Individual drugs will benefit too. Roche will continue to be the leading company in the cancer-treating drugs market throughout the study’s forecast period. Through emerging technologies and increasing demand in developed and developing countries, the future of cancer treatments holds great promise. That revenue growth will be mainly owing to the worldwide increase in cancer incidence and prevalence. New opportunities for cancer treatment exist, with high sales likely from many drugs – small-molecule products and biological agents (biologicals) – to 2022. Also, R&D pipelines in oncology are strong, including those for monoclonal antibodies (MAbs).The visiongain pharmaceutical industry analyst at visiongain, said, “Although oncology is one of the most researched areas of medicine, there remain un-met and under-met treatment needs. There is a need for well targeted therapies with better safety and efficacy. It is crucial that anti-cancer drugs have minimal side effects, so that the quality of patients’ lives can be enhanced. Pharma companies will further explore this field, making therapeutic progress this decade. In particular, companion diagnostic tests with drugs will help in cancer treatment, giving more-personalised, better-targeted medicine.”
European Medicines Agency Approves Orphan Medicinal Product Application of DCPrime’s Acute Myeloid Leukemia Vaccine
Pubblicato da fidest su giovedì, 2 febbraio 2012
Amsterdam Biotechnology company DCPrime today announces that the Committee for Orphan Medical Products (COMP) of the European Medicines Agency has issued a positive opinion recommending DCPrime’s application for orphan drug designation of, the company’s dendritic cell-based cancer vaccine candidate, which targets Acute Myeloid Leukemia (AML).”This orphan drug designation is a major step in DCPrime’s work towards approval of our AML vaccine, and clearly reflects the COMP’s view of the potential of this vaccine in improving survival of patients with AML”, said DCPime’s CEO and CSO Dr. Ada Kruisbeek. “At the present time, AML patients lack an approved therapy to prevent the cancer from returning after standard chemotherapy. In 75% of the patients treated, the leukemia returns within 2 years. Our vaccine is intended as a therapy to prevent the cancer from coming back, and in our current clinical study we are establishing if we can delay or prevent AML from returning. If we succeed, this will improve survival outcomes in AML.”
Orphan drug designation is granted to products aimed at treatment of a rare disease or condition that affects fewer than 5 per 10,000 people in the European Community. As a result, DCPrime will be eligible to receive a number of benefits, including fee reduction, valuable scientific advice to optimize development and guidance on clinical design, and extended allowance for marketing exclusivity after the drug’s approval for a period of up to ten years.
DCPrime is a Dutch clinical stage company, dedicated to developing cancer vaccines based on its proprietary dendritic cell (DC) technology platform DCOne™. With this platform, the company can generate off-the-shelf DC-based vaccines for a broad range of cancer types. DCOne™-based DC vaccines share all immune-stimulatory properties with patient derived DC-based vaccines, and have the simple logistics of off-the-shelf products. DCPrime’s lead product DCP-001 is in the clinic in a Phase I/IIa study in patients with Acute Myeloid Leukemia (AML).
Pubblicato da fidest su martedì, 16 agosto 2011
Gli scienziati del britannico Institute of Cancer Research hanno scoperto come le cellule cancerose siano in grado di “muoversi” trasformandosi in tumori, offrendo importanti spunti per la messa a punto di nuovi farmaci per prevenirne la diffusione. Una notizia che secondo Giovanni D’Agata, componente del Dipartimento Tematico Nazionale “Tutela del Consumatore” di Italia dei Valori e fondatore dello “Sportello dei Diritti”, non deve rimanere circoscritta al ristretto mondo della scienza, ma dev’essere conosciuta anche dai profani, affinché la ricerca stessa sia spronata nell’incessante studio per debellare questa grande piaga che incombe sull’umanità. I ricercatori sono convinti di aver identificato una proteina denominata “JAK” che aiuta le cellule tumorali generando la forza necessaria a muoversi. Come è noto, infatti, quando il cancro si sviluppa, con il noto processo chiamato metastasi, diventa molto più difficile da trattare, tanto che si pensa che il 90% delle morti conseguenti a tumori si verifichi dopo il sorgere delle metastasi. Gli scienziati dell’istituto di ricerca britannico, che hanno indagato sulle sostanze chimiche coinvolte nella migrazione cellulare nel melanoma – il famigerato cancro della pelle – sostengono che i processi venivano controllate dalla stessa sostanza chimica ossia la stessa molecola, chiamata “JAK”. La molecola “JAK” non è un nome nuovo tra le molecole studiate come “colpevoli” nei processi legati allo svilupparsi tumori. La stessa proteina è stata già presa di mira dagli scienziati nella lotta alla leucemia, tant’è che sono già allo studio alcuni farmaci che sono già in fase di sviluppo. Lo studio in questione ha rivelato che tali farmaci potrebbero anche arrestare la diffusione del cancro ed hanno pensato di effettuare già nei prossimi anni studi clinici per verificare se questi agenti potranno fermare la diffusione delle cellule tumorali nel corpo umano. Secondo il dottor Lesley Walker, direttore del Cancer Research UK, quella in corso sarà una sfida gigantesca nel trattamento del cancro che servirà ad impedirne la diffusione in tutto il corpo e a mantenerlo a bada una volta già diffuso.
Pubblicato da fidest su giovedì, 9 giugno 2011
Importanti passi in avanti nel trattamento del melanoma, un tumore della pelle particolarmente aggressivo che ogni anno nel nostro Paese fa registrare 7000 nuove diagnosi e 1500 decessi. Ipilimumab, un nuovo anticorpo monoclonale sviluppato da Bristol-Myers Squibb, associato al trattamento chemioterapico tradizionale, la dacarbazina, ha dimostrato di migliorare in maniera significativa la sopravvivenza dei pazienti colpiti da questo tumore nella forma metastatica. I dati, pubblicati anche sulla prestigiosa rivista scientifica “New England Journal of Medicine”, sono stati presentati ieri pomeriggio in sessione plenaria al 47° Congresso ASCO (American Society of Clinical Oncology), il più importante congresso mondiale di oncologia in corso a Chicago fino al 7 giugno, con la partecipazione di oltre 30.000 specialisti. La ricerca, che analizza per la prima volta la sopravvivenza a tre anni, ha coinvolto 500 persone colpite da melanoma metastatico e non trattate prima con altre terapie. A un anno sopravvive il 47,3% dei pazienti trattati con la combinazione costituita da ipilimumab associato alla dacarbazina rispetto al 36,3% di quelli trattati con il chemioterapico tradizionale; a 24 mesi il 28,5% contro il 17,9%, a tre anni il 20,8% contro il 12,2%. Si tratta di un risultato mai raggiunto prima. Con la terapia standard la sopravvivenza media è infatti di 6-9 mesi a cinque anni.
Pubblicato da fidest su mercoledì, 17 novembre 2010
Dublin, Ireland, (Globe Newswire) — After recent consultation with the FDA in November 2010, Merrion is preparing for its Phase III study for Orazol™. If successful, the Phase III study will allow a new drug application for Orazol to be made under the FDA’s abbreviated approval procedure section 505(b)(2) using a single Phase III study. The study will compare Orazol against placebo as an adjuvant breast cancer treatment with a primary endpoint of Disease Free Survival of patients with breast cancer. If approved, this drug would provide a new treatment, which could improve prognosis, in combination with existing treatments, for early stage breast cancer patients. Merrion has been focused on an oral form of this drug (zoledronic acid) for the bone metastases indication. However this trial would expand Orazol’s potential by allowing Orazol to be used for early treatment of breast cancer in addition to bone metastases for late stage cancer patients. Zoledronic acid has been shown to improve Disease Free Survival in large-scale Phase III clinical studies, involving thousands of breast cancer patients. Merrion has previously received scientific advice from the Committee for Medicinal Products for Human Use (CHMP) agreeing the approval pathway for Orazol in Europe for the existing bone metastases indication. Following a licensing agreement, Merrion would seek agreement from the CHMP to expand the use of Orazol to earlier stage breast cancer treatment.
Orazol, Merrion’s lead product, is a unique tablet formulation of zoledronic acid, made possible by Merrion’s proprietary GIPET® technology, and for which there are issued US Orazol patents to 2027. Orazol provides an ideal product profile to address the market needs, as a well-tolerated tablet formulation with weekly dosing. http://www.merrionpharma.com
Pubblicato da fidest su mercoledì, 28 aprile 2010
La terapia combinata trimodale (Cmt) a base di brachiterapia, radioterapia esterna e soppressione androgenica riduce il rischio di mortalità per carcinoma prostatico, rispetto alla sola brachiterapia, in uomini anziani a elevato rischio di questo tumore, senza problemi cardiovascolari o corretti mediante chirurgia. È quanto concludono, in uno studio pubblicato su Cancer, alcuni ricercatori del Department of radiation oncology, Brigham and Women’s hospital and Dana-Farber Cancer Institute di Boston. All’indagine hanno preso parte 764 uomini, d’età pari o superiore a 65 anni, a elevato rischio di tumore alla prostata che sono stati sottoposti alla sola brachiterapia o alla terapia combinata. I partecipanti non avevano mai subito infarto del miocardio oppure, dopo episodi infartuali, erano stati trattati mediante impianto di stent oppure intervento chirurgico. Dopo un follow-up medio di 4,9 anni, sono deceduti 25 uomini per cancro alla prostata. Effettuate le opportune correzioni per età e fattori prognostici per questo tumore, il rischio di mortalità è apparso molto più basso dopo l’esposizione a Cmt che dopo brachiterapia (hazard ratio = 0,29). Tra i fattori associati a un aumento del rischio di decesso è stato individuato un punteggio di Gleason compreso tra 8 e 10. «Aggressivi trattamenti loco-regionali sono, quindi, da suggerire in anziani sani a elevato rischio di cancro prostatico» conclude Hoffman KE, principale autore dello studio. Cancer. 2010 Mar 22. [Epub ahead of print] (fonte doctor news)
Pubblicato da fidest su giovedì, 13 agosto 2009
Copenhagen, Denmark Genmab A/S (OMX: GEN) announced top-line results from the Phase II study of Arzerra(TM) (ofatumumab) in combination with fludarabine and cyclophosphamide (FC) to treat chronic lymphocytic leukemia (CLL) in previously untreated patients. A total of 61 patients were treated in the study. Treatment response was assessed using the 1996 National Cancer Institute Guidelines. The complete remission rate was 32% in patients who received 500 mg of ofatumumab (n=31) and 50% in patients who received 1000 mg of ofatumumab (n=30). The overall response rate was 77% in the 500 mg treatment group and 73% in the 1000 mg treatment group.There were no unexpected safety findings reported during treatment and within 30 days after last infusion. The most common adverse event reported was neutropenia at 48%. Other common adverse events (greater that 15 percent) were nausea, leukopenia, rash, vomiting, pyrexia, headache and thrombocytopenia. The number of patients, who experienced adverse events, including serious adverse events, was similar between the two dose groups. One death was reported and was judged by the investigator as unrelated to ofatumumab. Patients in this open label study were randomized into two treatment groups. Each patient was to receive one infusion of 300 mg of ofatumumab in combination with FC followed by 5 monthly infusions of either 500 or 1000 mg of ofatumumab in combination with FC. Disease status was measured every 4 weeks until week 24 and every 3 months thereafter until disease progression or 24 months. Treatment response was assessed according to the 1996 National Cancer Institute Working Group guidelines by an Independent endpoints Review Committee. Patients nothaving progressed on their disease at 24 months will be followed for disease progression at 6 month intervals until 60 months.The objective of the study was to determine the efficacy of ofatumumab in combination with FC in previously untreated CLL patients. The primary endpoint was complete remission rate from start of treatment until 3 months aftelast infusion. Ofatumumab is a novel, investigational, fully human monoclonal antibody that targets a membrane-proximal (close to the cell surface) small loop epitope (a portion of a molecule to which an antibody binds) on the CD20 molecule of B-cells. This epitope is different from the binding sites targeted by other CD20 antibodies currently available.The CD20 molecule is a key target in CLLtherapy because it is expressed on most B-cells in CLL patients. Ofatumumab is being developed under a co-development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved in any country http://www.genmab.com Genma is a leading international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab’s world class discovery, development and manufacturing teams are using cutting-edge technology to create and develop products to address unmet medical needs. Our primary goal is to improve the lives of patients who are in urgent need of new treatment options. For more information on Genmab’s products and technology, visit
Pubblicato da fidest su mercoledì, 27 maggio 2009
Geneva World Health Organization (WHO) Director-General, Dr. Margaret Chan has appointed Ambassador Nancy Goodman Brinker, Founder of Susan G. Komen for the Cure®, a breast cancer foundation, as WHO Goodwill Ambassador for Cancer Control As Goodwill Ambassador, Ambassador Brinker is expected to raise awareness about cancer as a global public health problem. She will also advocate for strengthening global action for cancer prevention and control in the context of the Global Strategy for the Prevention and Control of Noncommunicable Diseases endorsed by the World Health Assembly in May 2008. Her messages will emphasize the need for low- and middle income countries to strengthen comprehensive and evidence-based cancer control policies and programmes. “I am very pleased to appoint Ambassador Nancy Brinker as a Goodwill Ambassador for WHO,” said WHO Director-General Margaret Chan. “I look forward to Ambassador Brinker’s help in raising global awareness of the need for comprehensive cancer control policies. The disease burden has shifted from wealthier to less affluent countries, and her advocacy will help in building awareness in low- and middle-income countries. Ambassador Brinker served as United States Ambassador to Hungary from 2001 to 2003 and as U.S. Chief of Protocol from 2007 to 2009. During her career as a businesswoman, consultant, health care advocate and philanthropist, she has received many awards. Ambassador Brinker has served on various boards, including Harvard University’s School of Public Health and was appointed by President Reagan to serve on the National Cancer Advisory Board at the National Cancer Institute. With former First Lady Laura Bush, Ambassador Brinker helped launch the U.S.-Middle East Partnership for Breast Cancer Awareness and Research in the areas of awareness-building, grassroots advocacy support, research, training, community outreach, and women’s empowerment. On her appointment as WHO Goodwill Ambassador, Ambassador Brinker said: “I would like to thank the WHO for this great honor and opportunity. If we raise awareness about the global burden of cancer, its socioeconomic and psychological consequences on cancer patients and their families and the necessary actions for its control, we will be able to advance the global agenda in the fight against cancer. I will work diligently to effectively disseminate these messages to the world.”